Aquestive(US:AQST) Globenewswire·2026-03-06 16:57Group 1 - A shareholder class action lawsuit has been filed against Aquestive Therapeutics, Inc. alleging that the company misled investors regarding the approval timeline for its New Drug Application for Anaphylm [1] - The lawsuit claims that the defendants created a false impression that the company was on track to receive approval by the January 31, 2026 Prescription Drug User Fee Act date [1] - Investors who purchased shares between June 16, 2025, and January 8, 2026, and suffered significant losses are encouraged to discuss their legal rights [2] Group 2 - The deadline for investors to request to be appointed as lead plaintiff in the case is May 4, 2026 [3] - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3] - The firm has been recognized as an ISS top-rated securities litigation law firm for multiple years [3]